Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Receives Average Rating of “Buy” from Brokerages

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) has been given an average rating of “Buy” by the seven research firms that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, four have assigned a buy rating and two have given a strong buy rating to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $14.3333.

A number of equities research analysts have issued reports on EPRX shares. HC Wainwright reiterated a “buy” rating and issued a $12.00 target price on shares of Eupraxia Pharmaceuticals in a research note on Friday, January 9th. Leede Financial upgraded shares of Eupraxia Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, October 29th. Cantor Fitzgerald upped their target price on shares of Eupraxia Pharmaceuticals from $11.00 to $19.00 and gave the stock an “overweight” rating in a research report on Thursday, January 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a research note on Wednesday, October 8th. Finally, Wall Street Zen upgraded Eupraxia Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, December 13th.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Alyeska Investment Group L.P. bought a new position in shares of Eupraxia Pharmaceuticals in the third quarter worth $1,475,000. Vivo Capital LLC acquired a new stake in Eupraxia Pharmaceuticals in the third quarter worth about $7,965,000. Velan Capital Investment Management LP acquired a new stake in Eupraxia Pharmaceuticals in the third quarter worth about $2,077,000. Integrated Wealth Concepts LLC bought a new position in Eupraxia Pharmaceuticals in the 3rd quarter valued at about $71,000. Finally, Bank of America Corp DE increased its stake in Eupraxia Pharmaceuticals by 262.9% during the 3rd quarter. Bank of America Corp DE now owns 45,577 shares of the company’s stock valued at $269,000 after buying an additional 33,018 shares during the period.

Eupraxia Pharmaceuticals Stock Down 0.2%

Shares of NASDAQ EPRX opened at $8.75 on Thursday. The firm’s 50-day moving average price is $6.91 and its two-hundred day moving average price is $6.03. Eupraxia Pharmaceuticals has a 52-week low of $2.68 and a 52-week high of $8.89. The stock has a market capitalization of $314.65 million, a P/E ratio of -10.06 and a beta of 1.21.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last announced its quarterly earnings results on Tuesday, November 4th. The company reported ($0.19) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.04. As a group, equities research analysts expect that Eupraxia Pharmaceuticals will post -0.67 earnings per share for the current year.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.